Delving into the Latest Updates on Small-molecule inhibitor of C5(Novartis) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

C5

Action

inhibitors

Mechanism

C5 inhibitors(Complement C5 inhibitors)

Therapeutic Areas

Hemic and Lymphatic DiseasesUrogenital DiseasesOther Diseases

Active Indication

Hemolytic-Uremic Syndrome

Inactive Indication-

Originator Organization

Novartis AG

Active Organization

Novartis AG

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Capparelli, Michael ; Duca, Jose ; Jendza, Keith ; Salcius, Michael ; Romanowski, Michael J ; Ferrara, Luciana ; Mogi, Muneto ; Kato, Mitsunori ; Mainolfi, Nello ; Be, Celine ; Tichkule, Ritesh ; Murphy, Jason ; De Erkenez, Andrea ; Horton, Patricia A ; Darsigny, Veronique ; Wiesmann, Christian ; Bolduc, Philippe ; Meredith, Erik ; Srinivas, Honnappa ; Namil, Abdel ; Heyder, Jessica ; Schirle, Markus ; Michaud, Gregory A ; Liu, Fang ; Nguyen, Anh ; Anderson, Karen ; McLaughlin, Doug

The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria. Here, we report the identification, optimization and mechanism of action for the first small-molecule inhibitor of C5 complement protein.

100 Deals associated with Small-molecule inhibitor of C5(Novartis)

Login to view more data